Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

multi-kinase inhibitor ST-1898

An orally bioavailable small molecule inhibitor of multiple receptor tyrosine kinases (RTKs), with potential antineoplastic activity. Upon oral administration, multi-kinase inhibitor ST-1898 inhibits the activity of multiple RTKs, which may include vascular endothelial growth factor receptor 2 (VEGFR-2; VEGFR2), hepatocyte growth factor receptor (HGFR; c-Met), AXL (UFO), platelet-derived growth factor receptor alpha (PDGFRa), rearranged during transfection (RET) and mast/stem cell factor receptor c-Kit (SCFR; CD117). This may result in antitumor activity in tumor cells in which these RTKs are upregulated or dysregulated.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:multi-target tyrosine kinase inhibitor ST-1898
Code name:ST 1898
ST-1898
ST1898
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search